Published in Am J Pathol on July 01, 2003
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics (2007) 1.24
Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A (2008) 1.14
Identification of the penta-EF-hand protein ALG-2 as a Ca2+-dependent interactor of mucolipin-1. J Biol Chem (2009) 0.99
ALG-2 attenuates COPII budding in vitro and stabilizes the Sec23/Sec31A complex. PLoS One (2013) 0.86
Ca2+ binding to EF hands 1 and 3 is essential for the interaction of apoptosis-linked gene-2 with Alix/AIP1 in ocular melanoma. Biochemistry (2004) 0.85
Significance of calcium binding, tyrosine phosphorylation, and lysine trimethylation for the essential function of calmodulin in vertebrate cells analyzed in a novel gene replacement system. J Biol Chem (2012) 0.83
Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries. Open Biochem J (2008) 0.83
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. J Transl Med (2012) 0.81
Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PLoS One (2015) 0.80
The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-inducible gene product localized at the endoplasmic reticulum membrane. Arch Biochem Biophys (2007) 0.80
Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects. Ann Clin Lab Sci (2009) 0.78
Apoptosis-linked gene 2 promotes breast cancer growth and metastasis by regulating the cytoskeleton. Oncotarget (2016) 0.78
Structural and Functional Study of Apoptosis-linked Gene-2/Heme-binding Protein 2 Interactions in HIV-1 Production. J Biol Chem (2016) 0.75
Variations in the PDCD6 gene are associated with increased uterine leiomyoma risk in the Chinese. Genet Test Mol Biomarkers (2013) 0.75
Single nucleotide polymorphisms in PDCD6 gene are associated with the development of cervical squamous cell carcinoma. Fam Cancer (2015) 0.75
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer (2002) 14.94
Cancer statistics, 2001. CA Cancer J Clin (2001) 11.73
Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature (2002) 3.99
Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science (1996) 2.69
Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ (1999) 1.99
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
Cloning of AIP1, a novel protein that associates with the apoptosis-linked gene ALG-2 in a Ca2+-dependent reaction. J Biol Chem (1999) 1.83
Alix (ALG-2-interacting protein X), a protein involved in apoptosis, binds to endophilins and induces cytoplasmic vacuolization. J Biol Chem (2002) 1.67
A novel integrin-activated pathway forms PKB/Akt-stimulatory phosphatidylinositol 3,4-bisphosphate via phosphatidylinositol 3-phosphate in platelets. J Biol Chem (1998) 1.58
Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med (2002) 1.54
The glioma-associated protein SETA interacts with AIP1/Alix and ALG-2 and modulates apoptosis in astrocytes. J Biol Chem (2000) 1.47
Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein. EMBO J (2000) 1.41
Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun (2000) 1.33
BRO1, a novel gene that interacts with components of the Pkc1p-mitogen-activated protein kinase pathway in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.25
Apoptosis-linked gene 2 binds to the death domain of Fas and dissociates from Fas during Fas-mediated apoptosis in Jurkat cells. Biochem Biophys Res Commun (2001) 1.05
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner. J Biol Chem (2001) 1.05
The penta-EF-hand domain of ALG-2 interacts with amino-terminal domains of both annexin VII and annexin XI in a Ca2+-dependent manner. Biochim Biophys Acta (2002) 1.01
ALG-2 interacts with the amino-terminal domain of annexin XI in a Ca(2+)-dependent manner. Biochem Biophys Res Commun (2002) 1.00
Apoptosis-linked gene 2-deficient mice exhibit normal T-cell development and function. Mol Cell Biol (2002) 0.99
Two forms of the apoptosis-linked protein ALG-2 with different Ca(2+) affinities and target recognition. J Biol Chem (2000) 0.97
SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro Oncol (2000) 0.95
Interaction of ALG-2 with ASK1 influences ASK1 localization and subsequent JNK activation. FEBS Lett (2002) 0.95
ALG-2: a Ca2+ -binding modulator protein involved in cell proliferation and in cell death. Biochim Biophys Acta (2002) 0.93
Identification and cloning of xp95, a putative signal transduction protein in Xenopus oocytes. J Biol Chem (1999) 0.89
Dissociation of apoptosis and activation of IL-1beta-converting enzyme/Ced-3 proteases by ALG-2 and the truncated Alzheimer's gene ALG-3. J Immunol (1997) 0.87
Increased expression of apoptosis-linked gene 2 (ALG2) in the rat brain after temporary focal cerebral ischemia. Neuroscience (2000) 0.85
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol (2005) 4.54
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol (2002) 4.45
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J (2008) 3.86
ATM activation in normal human tissues and testicular cancer. Cell Cycle (2005) 2.25
Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol (2003) 2.25
Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics (2006) 1.73
Epidermal growth factor-mediated activation of the ETS domain transcription factor Elk-1 requires nuclear calcium. J Biol Chem (2002) 1.53
Human Xip1 (C2orf13) is a novel regulator of cellular responses to DNA strand breaks. J Biol Chem (2007) 1.38
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther (2006) 1.37
Culprit and victim -- DNA topoisomerase II. Lancet Oncol (2002) 1.26
Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun (2008) 1.16
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology (2009) 1.14
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology (2010) 1.13
Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res (2006) 1.09
MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res (2006) 1.08
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology (2008) 1.07
Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One (2010) 1.06
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther (2010) 1.04
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer (2013) 1.03
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res (2005) 1.02
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol (2002) 0.97
ALG-2 oscillates in subcellular localization, unitemporally with calcium oscillations. Biochem Biophys Res Commun (2006) 0.93
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol (2006) 0.93
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer (2010) 0.92
Pathology economic model tool: a novel approach to workflow and budget cost analysis in an anatomic pathology laboratory. Arch Pathol Lab Med (2010) 0.92
ALG-2, a multifunctional calcium binding protein? Front Biosci (2004) 0.90
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS (2011) 0.90
Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med (2011) 0.89
The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol (2007) 0.89
ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell death. Biochem Biophys Res Commun (2008) 0.88
ALG-2 attenuates COPII budding in vitro and stabilizes the Sec23/Sec31A complex. PLoS One (2013) 0.86
Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs (2009) 0.86
Properties of the co-chaperone protein p23 erroneously attributed to ALG-2 (apoptosis-linked gene 2). FEBS Lett (2003) 0.86
Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark (2008) 0.83
Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. J Biol Chem (2005) 0.83
Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance. Biochemistry (2002) 0.83
Significance of calcium binding, tyrosine phosphorylation, and lysine trimethylation for the essential function of calmodulin in vertebrate cells analyzed in a novel gene replacement system. J Biol Chem (2012) 0.83
The co-chaperone p23 is degraded by caspases and the proteasome during apoptosis. FEBS Lett (2005) 0.83
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer (2008) 0.83
[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. PLoS One (2013) 0.82
Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res (2005) 0.81
[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice. PLoS One (2012) 0.81
A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo. Mol Pharmacol (2007) 0.81
A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells. J Biol Chem (2004) 0.81
Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin. J Biol Chem (2011) 0.81
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha. FEBS Lett (2002) 0.81
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol (2005) 0.81
A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol Pharmacol (2006) 0.81
Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR. Eur J Med Chem (2008) 0.80
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. J Med Chem (2013) 0.80
The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-inducible gene product localized at the endoplasmic reticulum membrane. Arch Biochem Biophys (2007) 0.80
Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. J Gene Med (2012) 0.79
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. Cardiovasc Toxicol (2007) 0.79
Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS (2008) 0.79
Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones. J Med Chem (2010) 0.79
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha. Mol Pharmacol (2003) 0.79
Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential. Cancer Chemother Pharmacol (2010) 0.78
Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori (2009) 0.78
Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance. Biochemistry (2003) 0.78
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. BMC Pharmacol (2004) 0.78
Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol (2007) 0.78
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat. Electrophoresis (2010) 0.77
The PEF family proteins sorcin and grancalcin interact in vivo and in vitro. FEBS Lett (2003) 0.77
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol (2003) 0.77
The LTR promoter of the rat oncomodulin gene is regulated by cell-line specific accessibility in the LTR U3 region. Arch Biochem Biophys (2006) 0.77
A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology (2010) 0.77
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother Pharmacol (2003) 0.76
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res (2005) 0.76
A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha. Biochem Pharmacol (2003) 0.75
Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II. Biochem Biophys Res Commun (2005) 0.75
Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice. Exp Dermatol (2008) 0.75
Ossifying thymoma associated with refractory myasthenia gravis. APMIS (2010) 0.75
Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemother Pharmacol (2011) 0.75